# Treatment options for Duchenne muscular dystrophy
Treatment of Duchenne muscular dystrophy focuses on slowing muscle breakdown, preventing complications, and maintaining quality of life. There is no cure that stops the disease, but in recent years treatments have become available that can slow progression, especially when started early. Treatment is adjusted as the disease progresses.
Corticosteroids
ProveniIncluded in official guidelines, or approved by EMA or FDA
Corticosteroids (particularly prednisone) have been the cornerstone of Duchenne muscular dystrophy treatment for decades. They reduce the inflammatory response in damaged muscles, thereby slowing muscle breakdown. Most boys are offered corticosteroids as soon as diagnosis is confirmed.
The medication works by suppressing the immune system, so fewer inflammatory cells travel to the muscles. This helps slow the loss of muscle strength and can maintain certain milestones (such as the ability to walk independently) for longer.
Known side effects of long-term corticosteroids include weight gain, increased appetite, mood swings, sleep problems, bone loss (osteoporosis), and increased susceptibility to infections. For this reason, treatment effectiveness and side effects are regularly monitored.
Vamorolone
ProveniIncluded in official guidelines, or approved by EMA or FDA
Vamorolone is a newer medication that belongs to the same family as corticosteroids but works differently on the body. It has anti-inflammatory and antioxidant effects. Vamorolone has been approved by regulatory authorities and can be used as an alternative or supplement to traditional corticosteroids.
Research shows that vamorolone can be effective in slowing muscle breakdown, possibly with fewer side effects on bones and growth than classical corticosteroids. This makes it particularly interesting for children where bone health or growth is a concern. Side effects are generally mild to moderate and may include headache, nausea, and abdominal pain.
Physiotherapy and Movement Training
ProveniIncluded in official guidelines, or approved by EMA or FDA
Regular physiotherapy and tailored movement exercises are an essential part of treatment. Physiotherapists help maintain joint flexibility, prevent spastic contractures (muscle shortening), and make the best use of remaining muscle strength.
As the disease progresses, the emphasis shifts from strengthening exercises to maintaining freedom of movement and preventing deformities. Later in the disease course, physiotherapy helps with adapted seating, standing frames, and transfers.
Recent research suggests that certain training methods (such as virtual reality training and specific balance exercises) can be useful additions. Side effects are unlikely; the main risks lie rather in insufficient or incorrect execution.
Orthopedic support and aids
ProveniIncluded in official guidelines, or approved by EMA or FDA
As muscles weaken, orthopedic aids become increasingly important: ankle braces, leg splints, gait trainers, walkers, and eventually wheelchairs. These allow children to remain mobile for longer and reduce fall risks.
Surgical interventions (for example, lengthening procedures for shortened muscles, correcting spinal abnormalities) are considered at certain stages, always in consultation with surgeons specialized in neuromuscular disorders. These interventions can help improve mobility and quality of life.
Cardiac monitoring and treatment
ProveniIncluded in official guidelines, or approved by EMA or FDA
Because Duchenne muscular dystrophy also affects the heart muscle, regular cardiac monitoring is essential. Echocardiograms are performed periodically to assess the heart's pumping function.
When the heart muscle shows signs of weakness, various medications can be prescribed to combat heart failure, such as ACE inhibitors, beta-blockers, or SGLT2 inhibitors. These are aimed at protecting the heart and preventing progressive heart failure.
Respiratory support
ProveniIncluded in official guidelines, or approved by EMA or FDA
As the disease progresses, the breathing muscles weaken. This can lead to sleep problems and breathing difficulties. Non-invasive ventilation (via a mask) at night helps improve oxygen uptake and reduces the workload on the breathing muscles.
Towards the end of the disease course, complete ventilatory support may be needed. Regular monitoring of lung function helps to estimate the timing of intervention.
Nutrition and swallowing care
ProveniIncluded in official guidelines, or approved by EMA or FDA
Many boys with Duchenne muscular dystrophy have difficulty swallowing, especially as the disease progresses. This requires careful eating, adapted food consistency and sometimes speech therapy guidance.
In later stages, a feeding tube (gastric tube) may be needed to prevent malnutrition and minimize the risk of aspiration. Regular screening for swallowing problems helps detect complications early.
Exon-skipping therapies
ResearchediPositive results in clinical studies, not yet standard treatment
Exon-skipping therapies are medicines being investigated in research settings. They work by skipping specific parts (exons) of the damaged gene, allowing the body to produce a shortened but still functional version of the dystrophin protein.
These treatments are suitable for boys with specific mutations. Studies show that exon-skipping works best when started early in the disease course. Not all mutations have a suitable exon-skipping therapy yet; researchers are working on further developments.
Side effects are generally mild, but because these therapies are relatively new, safety is continuously monitored.
Geneantikodons therapies and antisense oligonucleotides
ResearchediPositive results in clinical studies, not yet standard treatment
These are injections containing genetic material that can block or bypass the mutation in the DNA. They target specific mutations and help the body produce more functional dystrophin protein.
Studies show positive effects on muscle strength and rate of decline. These therapies are in various stages of clinical trials; some are in later trial phases. They are administered intrathecally or intramuscularly.
Gene therapy
ResearchediPositive results in clinical studies, not yet standard treatment
Gene therapy attempts to directly repair or replace the defective gene. A promising approach is gene therapy with viral vectors (especially AAV), whereby a healthy gene is introduced into muscles.
Recently published studies show that gene therapy with prophylactic management (for example, with immunosuppressants to prevent the body from rejecting the genetic construct) can be safe and effective. This is still experimental and available in research settings, but given the recent positive results, it is regarded as an important research area.
Side effects can include inflammatory reactions and immune responses; therefore, close monitoring is provided.
Cell therapy (heart stem cells)
ResearchediPositive results in clinical studies, not yet standard treatment
A number of studies are investigating whether heart cells derived from donor or patient can help improve heart function. This is specifically aimed at the cardiomyopathy that occurs in Duchenne muscular dystrophy.
The HOPE-3 study investigated deramyocell (heart stem cells). These therapies are still in clinical trials.
Antioxidants and anti-inflammatory agents
ResearchediPositive results in clinical studies, not yet standard treatment
Because oxidative stress plays a role in muscle breakdown, medicines are being investigated that can counteract this. These include coenzyme Q10, antioxidants and specific anti-inflammatory agents.
Effectiveness has been modest so far. They are sometimes used as a supplement to other treatments, but do not yet form standard treatment.
CRISPR gene editing
ExperimentaliOngoing in study setting, outcome still unknown
CRISPR-Cas9 is a technique that can edit DNA. Studies are investigating whether CRISPR can be introduced directly into muscle tissue to correct the mutation. This is still in early clinical phase.
This technique is promising but still highly experimental; side effects and long-term effects are not yet fully clarified.
Psychosocial and social support
ProveniIncluded in official guidelines, or approved by EMA or FDA
Psychosocial support, counseling, and contact with peers and families have proven effective in coping with the psychological burden of the disease. Many treatment centers provide access to psychologists, social workers, and patient organizations.
Early involvement of psychosocial care providers can help with adjustment and grieving processes and supports both patient and family.
Schooling and education
ProveniIncluded in official guidelines, or approved by EMA or FDA
Adapted education and the use of school support help children with Duchenne muscular dystrophy continue their education for as long as possible. This contributes to social participation and quality of life. Many schools work together with care providers on adaptations.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._